About Market Research Forecast

MR Forecast provides premium market intelligence on deep technologies that can cause a high level of disruption in the market within the next few years. When it comes to doing market viability analyses for technologies at very early phases of development, MR Forecast is second to none. What sets us apart is our set of market estimates based on secondary research data, which in turn gets validated through primary research by key companies in the target market and other stakeholders. It only covers technologies pertaining to Healthcare, IT, big data analysis, block chain technology, Artificial Intelligence (AI), Machine Learning (ML), Internet of Things (IoT), Energy & Power, Automobile, Agriculture, Electronics, Chemical & Materials, Machinery & Equipment's, Consumer Goods, and many others at MR Forecast. Market: The market section introduces the industry to readers, including an overview, business dynamics, competitive benchmarking, and firms' profiles. This enables readers to make decisions on market entry, expansion, and exit in certain nations, regions, or worldwide. Application: We give painstaking attention to the study of every product and technology, along with its use case and user categories, under our research solutions. From here on, the process delivers accurate market estimates and forecasts apart from the best and most meaningful insights.

Products generically come under this phrase and may imply any number of goods, components, materials, technology, or any combination thereof. Any business that wants to push an innovative agenda needs data on product definitions, pricing analysis, benchmarking and roadmaps on technology, demand analysis, and patents. Our research papers contain all that and much more in a depth that makes them incredibly actionable. Products broadly encompass a wide range of goods, components, materials, technologies, or any combination thereof. For businesses aiming to advance an innovative agenda, access to comprehensive data on product definitions, pricing analysis, benchmarking, technological roadmaps, demand analysis, and patents is essential. Our research papers provide in-depth insights into these areas and more, equipping organizations with actionable information that can drive strategic decision-making and enhance competitive positioning in the market.

U.S. Anti-Inflammatory Biologics Market

U.S. Anti-Inflammatory Biologics Market Report Probes the USD Billion Size, Share, Growth Report and Future Analysis by 2033

U.S. Anti-Inflammatory Biologics Market by Drug Class (Anti-Tumor Necrosis Factor (TNF), by Application (Rheumatoid Arthritis, Psoriasis, Others), by Route of Administration (Oral, Injection), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), by Forecast 2026-2034

Jan 21 2025

Base Year: 2025

180 Pages

U.S. Anti-Inflammatory Biologics Market Report Probes the USD Billion Size, Share, Growth Report and Future Analysis by 2033

Key Insights

The U.S. Anti-Inflammatory Biologics Market size was valued at USD 51.57 USD Billion in 2023 and is projected to reach USD 78.06 USD Billion by 2032, exhibiting a CAGR of 6.1 % during the forecast period. Anti-inflammatory biologics are a type of medication intended to do the reduction of the inflammatory processes in the body of the organism by the single-minded targeting of the joint molecules that are involved in the inflammatory response. RAID is mostly applied for treating autoimmune diseases like rheumatoid arthritis cancer, psoriasis, bowel disease, etc. There are different types of anti-inflammatory biologics: TNF inhibitors that are directed at the tumor necrosis factor, interleukin inhibitors, and JAK inhibitors working at the part of the inflammatory pathway. These biologics make individualized treatment with less aggregate toxins than regular anti-inflammatory drugs, resulting in smaller side effects. USA exhibition has shown the increasing tendency to use anti-inflammatory biologics, the rates of which are mostly based on the high occurrence of autoimmune diseases and the latest biotechnology.

U.S. Anti-Inflammatory Biologics Trends

Growing awareness and diagnosis of chronic inflammatory diseases
Development of novel biologics with enhanced efficacy and safety profiles
Shift towards personalized and combination therapies
Technological advancements in manufacturing and distribution channels

U.S. Anti-Inflammatory Biologics Market Market Size and Forecast (2024-2030) — U.S. Anti-Inflammatory Biologics Market Company Market Share

Driving Forces: What's Propelling the U.S. Anti-Inflammatory Biologics Market

Rising prevalence of chronic inflammatory diseases: The aging population, sedentary lifestyles, and environmental triggers contribute to the increasing prevalence of chronic inflammatory diseases, including rheumatoid arthritis, psoriasis, and inflammatory bowel disease. This surge in disease burden fuels the demand for effective and selective treatments.
Growing need for targeted therapies: Anti-inflammatory biologics provide targeted therapies that precisely inhibit specific inflammatory pathways. These therapies offer better outcomes and reduced side effects compared to traditional non-biologic drugs. By modulating the immune system and addressing underlying inflammatory processes, biologics have significantly transformed the treatment landscape for chronic inflammatory diseases.
Supportive government policies and initiatives: Governments and regulatory agencies actively promote research and innovation in the biologics sector. Funding for clinical trials, streamlined approval pathways, and incentives for innovation encourage pharmaceutical companies to invest in the development of new and improved anti-inflammatory biologics.
Technological advancements: Advances in biotechnology and genetic engineering have accelerated the discovery and development of novel anti-inflammatory biologics. These advancements have led to the development of biologics with enhanced target specificity, efficacy, and tolerability.

Challenges and Restraints in U.S. Anti-Inflammatory Biologics Market

High cost of biologics: Biologics are expensive to develop and manufacture, which can limit access for patients.
Safety concerns: Some biologics may cause adverse events or immunogenicity, requiring careful monitoring and risk management.
Growing competition: The market is becoming increasingly competitive with the entry of new players and generic alternatives.

Emerging Trends in U.S. Anti-Inflammatory Biologics

Biosimilars and generics: Biosimilars and generic biologics are becoming more prevalent, providing cost-effective alternatives to original biologics.
Precision medicine: Advancements in genomics and biomarkers are enabling personalized therapies tailored to individual patient profiles.
Artificial intelligence (AI): AI is being used to streamline drug discovery, clinical trials, and patient care for inflammatory diseases.

Growth Catalysts in U.S. Anti-Inflammatory Biologics Industry

R&D investments and innovations: Pharmaceutical companies are making significant investments in research and development to discover novel biologics with enhanced efficacy, safety, and specificity. They are exploring new therapeutic modalities, such as bispecific antibodies and antibody-drug conjugates, to further improve treatment outcomes.
Strategic partnerships and collaborations: Collaboration among pharmaceutical companies, research institutions, and patient advocacy groups fosters innovation and facilitates the advancement of anti-inflammatory biologics. These collaborations enable the sharing of expertise, resources, and patient data, accelerating drug development and improving access to treatment.
Favorable regulatory landscape: Regulatory agencies, such as the FDA, prioritize the evaluation and approval of new anti-inflammatory biologics. They focus on assessing safety and efficacy to ensure patients have access to innovative treatments while maintaining high standards of patient care.
Increasing patient awareness and demand: Growing awareness of chronic inflammatory diseases and their treatments among patients and healthcare providers fuels the demand for anti-inflammatory biologics. Patient-driven initiatives and advocacy groups play a significant role in educating and empowering patients to seek appropriate care.

Leading Players in the U.S. Anti-Inflammatory Biologics Market

Significant Developments in U.S. Anti-Inflammatory Biologics Sector

November 2023: Merck announced the U.S. FDA approval of KEYTRUDA (pembrolizumab) for the treatment of moderate-to-severe active lupus nephritis.
October 2023: AbbVie announced positive topline results from a Phase 3 trial evaluating the efficacy and safety of upadacitinib in treating active psoriatic arthritis.
July 2023: Amgen reported positive results from a Phase 3 study investigating the safety and efficacy of tezepelumab in treating systemic lupus erythematosus.

Comprehensive Coverage U.S. Anti-Inflammatory Biologics Market Report

The comprehensive coverage of the U.S. anti-inflammatory biologics market report includes:

Market size and forecast
Market segmentation and key trends
Driving forces and challenges
Competitive landscape and leading players
Industry developments and case studies
Regulatory framework and policy analysis
prospects and growth opportunities

Pricing Analysis

The report analyzes the pricing strategies of leading players in the U.S. anti-inflammatory biologics market, considering factors such as:

Drug formulation
Dosage
Market competition
Government regulations

Import And Export Analysis

The report provides an overview of the import and export trends of anti-inflammatory biologics in the U.S., focusing on:

Key trading countries
Import and export volumes
Customs regulations

Segmentation

Drug Class:

Anti-TNF (Tumor Necrosis Factor)
Anti-IL-1 (Interleukin-1)
Anti-IL-6 (Interleukin-6)
Others

Application:

Rheumatoid Arthritis
Psoriasis
Inflammatory Bowel Disease
Others

Route of Administration:

Oral
Injection

Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Patent/Trademark Analysis

The report provides an analysis of patents and trademarks related to anti-inflammatory biologics in the U.S., including:

Patent expiration dates
Trademark protection
Intellectual property strategies

U.S. Anti-Inflammatory Biologics Market REPORT HIGHLIGHTS

Aspects	Details
Study Period	2020-2034
Base Year	2025
Estimated Year	2026
Forecast Period	2026-2034
Historical Period	2020-2025
Growth Rate	CAGR of 6.1 % from 2020-2034
Segmentation	By Drug Class Anti-Tumor Necrosis Factor (TNF By Application Rheumatoid Arthritis Psoriasis Others By Route of Administration Oral Injection By Distribution Channel Hospital Pharmacies Retail Pharmacies Online Pharmacies By Geography

1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
- 2.1. Introduction
3. Market Dynamics
- 3.1. Introduction
- - 3.2. Market Drivers
  - - 3.2.1. Surging Inflammatory Diseases Incidence to Boost the Demand for Anti-inflammatory Biologics
- - 3.3. Market Restrains
  - - 3.3.1. Limited Preference for Anti-Inflammatory Biologics as the Initial Treatment to Impede the Adoption of These Drugs
- - 3.4. Market Trends
  - - 3.4.1. Strong Focus on Development of Novel Anti-inflammatory Biologics to Drive Market Expansion
4. Market Factor Analysis
- 4.1. Porters Five Forces
- 4.2. Supply/Value Chain
- 4.3. PESTEL analysis
- 4.4. Market Entropy
- 4.5. Patent/Trademark Analysis
5. U.S. Anti-Inflammatory Biologics Market Analysis, Insights and Forecast, 2020-2032
- 5.1. Market Analysis, Insights and Forecast - by Drug Class
  - 5.1.1. Anti-Tumor Necrosis Factor (TNF
- 5.2. Market Analysis, Insights and Forecast - by Application
  - 5.2.1. Rheumatoid Arthritis
  - 5.2.2. Psoriasis
  - 5.2.3. Others
- 5.3. Market Analysis, Insights and Forecast - by Route of Administration
  - 5.3.1. Oral
  - 5.3.2. Injection
- 5.4. Market Analysis, Insights and Forecast - by Distribution Channel
  - 5.4.1. Hospital Pharmacies
  - 5.4.2. Retail Pharmacies
  - 5.4.3. Online Pharmacies
- 5.5. Market Analysis, Insights and Forecast - by Region
  - 5.5.1.
6. Competitive Analysis
- 6.1. Market Share Analysis 2025
- - 6.2. Company Profiles
  - - 6.2.1 AbbVie Inc. (U.S.)
      6.2.1.1. Overview
      6.2.1.2. Products
      6.2.1.3. SWOT Analysis
      6.2.1.4. Recent Developments
      6.2.1.5. Financials (Based on Availability)
    - 6.2.2 Merck & Co. Inc. (U.S.)
      6.2.2.1. Overview
      6.2.2.2. Products
      6.2.2.3. SWOT Analysis
      6.2.2.4. Recent Developments
      6.2.2.5. Financials (Based on Availability)
    - 6.2.3 Bristol-Myers Squibb Company (U.S.)
      6.2.3.1. Overview
      6.2.3.2. Products
      6.2.3.3. SWOT Analysis
      6.2.3.4. Recent Developments
      6.2.3.5. Financials (Based on Availability)
    - 6.2.4 Johnson & Johnson Services Inc. (U.S.)
      6.2.4.1. Overview
      6.2.4.2. Products
      6.2.4.3. SWOT Analysis
      6.2.4.4. Recent Developments
      6.2.4.5. Financials (Based on Availability)
    - 6.2.5 Pfizer Inc. (U.S.)
      6.2.5.1. Overview
      6.2.5.2. Products
      6.2.5.3. SWOT Analysis
      6.2.5.4. Recent Developments
      6.2.5.5. Financials (Based on Availability)
    - 6.2.6 Novartis AG (Switzerland)
      6.2.6.1. Overview
      6.2.6.2. Products
      6.2.6.3. SWOT Analysis
      6.2.6.4. Recent Developments
      6.2.6.5. Financials (Based on Availability)
    - 6.2.7 Eli Lilly and Company (U.S.)
      6.2.7.1. Overview
      6.2.7.2. Products
      6.2.7.3. SWOT Analysis
      6.2.7.4. Recent Developments
      6.2.7.5. Financials (Based on Availability)
    - 6.2.8 Amgen Inc. (U.S.)
      6.2.8.1. Overview
      6.2.8.2. Products
      6.2.8.3. SWOT Analysis
      6.2.8.4. Recent Developments
      6.2.8.5. Financials (Based on Availability)
    - 6.2.9 Sanofi S.A.
      6.2.9.1. Overview
      6.2.9.2. Products
      6.2.9.3. SWOT Analysis
      6.2.9.4. Recent Developments
      6.2.9.5. Financials (Based on Availability)
    - 6.2.10 Roche Holding AG
      6.2.10.1. Overview
      6.2.10.2. Products
      6.2.10.3. SWOT Analysis
      6.2.10.4. Recent Developments
      6.2.10.5. Financials (Based on Availability)

List of Figures

Figure 1: U.S. Anti-Inflammatory Biologics Market Revenue Breakdown (USD Billion, %) by Product 2025 & 2033
Figure 2: U.S. Anti-Inflammatory Biologics Market Share (%) by Company 2025

List of Tables

Table 1: U.S. Anti-Inflammatory Biologics Market Revenue USD Billion Forecast, by Drug Class 2020 & 2033
Table 2: U.S. Anti-Inflammatory Biologics Market Volume Kiloton Forecast, by Drug Class 2020 & 2033
Table 3: U.S. Anti-Inflammatory Biologics Market Revenue USD Billion Forecast, by Application 2020 & 2033
Table 4: U.S. Anti-Inflammatory Biologics Market Volume Kiloton Forecast, by Application 2020 & 2033
Table 5: U.S. Anti-Inflammatory Biologics Market Revenue USD Billion Forecast, by Route of Administration 2020 & 2033
Table 6: U.S. Anti-Inflammatory Biologics Market Volume Kiloton Forecast, by Route of Administration 2020 & 2033
Table 7: U.S. Anti-Inflammatory Biologics Market Revenue USD Billion Forecast, by Distribution Channel 2020 & 2033
Table 8: U.S. Anti-Inflammatory Biologics Market Volume Kiloton Forecast, by Distribution Channel 2020 & 2033
Table 9: U.S. Anti-Inflammatory Biologics Market Revenue USD Billion Forecast, by Region 2020 & 2033
Table 10: U.S. Anti-Inflammatory Biologics Market Volume Kiloton Forecast, by Region 2020 & 2033
Table 11: U.S. Anti-Inflammatory Biologics Market Revenue USD Billion Forecast, by Drug Class 2020 & 2033
Table 12: U.S. Anti-Inflammatory Biologics Market Volume Kiloton Forecast, by Drug Class 2020 & 2033
Table 13: U.S. Anti-Inflammatory Biologics Market Revenue USD Billion Forecast, by Application 2020 & 2033
Table 14: U.S. Anti-Inflammatory Biologics Market Volume Kiloton Forecast, by Application 2020 & 2033
Table 15: U.S. Anti-Inflammatory Biologics Market Revenue USD Billion Forecast, by Route of Administration 2020 & 2033
Table 16: U.S. Anti-Inflammatory Biologics Market Volume Kiloton Forecast, by Route of Administration 2020 & 2033
Table 17: U.S. Anti-Inflammatory Biologics Market Revenue USD Billion Forecast, by Distribution Channel 2020 & 2033
Table 18: U.S. Anti-Inflammatory Biologics Market Volume Kiloton Forecast, by Distribution Channel 2020 & 2033
Table 19: U.S. Anti-Inflammatory Biologics Market Revenue USD Billion Forecast, by Country 2020 & 2033
Table 20: U.S. Anti-Inflammatory Biologics Market Volume Kiloton Forecast, by Country 2020 & 2033

Methodology

Step 1 - Identification of Relevant Samples Size from Population Database

Step 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)

Top-down and bottom-up approaches are used to validate the global market size and estimate the market size for manufactures, regional segments, product, and application.

Note*: In applicable scenarios

Step 3 - Data Sources

Primary Research

Web Analytics
Survey Reports
Research Institute
Latest Research Reports
Opinion Leaders

Secondary Research

Annual Reports
White Paper
Latest Press Release
Industry Association
Paid Database
Investor Presentations

Step 4 - Data Triangulation

Involves using different sources of information in order to increase the validity of a study

These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.

Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.

During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence

Additionally, after gathering mixed and scattered data from a wide range of sources, data is triangulated and correlated to come up with estimated figures which are further validated through primary mediums or industry experts, opinion leaders.

Frequently Asked Questions

1. What is the projected Compound Annual Growth Rate (CAGR) of the U.S. Anti-Inflammatory Biologics Market?

The projected CAGR is approximately 6.1 %.

2. Which companies are prominent players in the U.S. Anti-Inflammatory Biologics Market?

Key companies in the market include AbbVie Inc. (U.S.), Merck & Co., Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), Johnson & Johnson Services, Inc. (U.S.), Pfizer Inc. (U.S.), Novartis AG (Switzerland), Eli Lilly and Company (U.S.), Amgen Inc. (U.S.), Sanofi S.A. , Roche Holding AG.

3. What are the main segments of the U.S. Anti-Inflammatory Biologics Market?

The market segments include Drug Class, Application, Route of Administration, Distribution Channel.

4. Can you provide details about the market size?

The market size is estimated to be USD 51.57 USD Billion as of 2022.

5. What are some drivers contributing to market growth?

Surging Inflammatory Diseases Incidence to Boost the Demand for Anti-inflammatory Biologics.

6. What are the notable trends driving market growth?

Strong Focus on Development of Novel Anti-inflammatory Biologics to Drive Market Expansion.

7. Are there any restraints impacting market growth?

Limited Preference for Anti-Inflammatory Biologics as the Initial Treatment to Impede the Adoption of These Drugs.

8. Can you provide examples of recent developments in the market?

October 2023: The U.S. FDA announced the approval of BIMZELX (bimekizumab-bkzx) for treating moderate-to-severe plaque psoriasis in patients who are candidates for phototherapy or systemic therapy.

9. What pricing options are available for accessing the report?

Pricing options include single-user, multi-user, and enterprise licenses priced at USD 2850, USD 3850, and USD 4850 respectively.

10. Is the market size provided in terms of value or volume?

The market size is provided in terms of value, measured in USD Billion and volume, measured in Kiloton.

11. Are there any specific market keywords associated with the report?

Yes, the market keyword associated with the report is "U.S. Anti-Inflammatory Biologics Market," which aids in identifying and referencing the specific market segment covered.

12. How do I determine which pricing option suits my needs best?

The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.

13. Are there any additional resources or data provided in the U.S. Anti-Inflammatory Biologics Market report?

While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available.

14. How can I stay updated on further developments or reports in the U.S. Anti-Inflammatory Biologics Market?

To stay informed about further developments, trends, and reports in the U.S. Anti-Inflammatory Biologics Market, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.

Get Free Sample

Pre Order Enquiry Request discount

Pricing

Related Reports

Anti-Inflammatory Biologics Market 2025-2033 Overview: Trends, Competitor Dynamics, and Opportunities

U.S. Inflammatory Bowel Disease Treatment Market 2025-2033 Analysis: Trends, Competitor Dynamics, and Growth Opportunities

Anti-Inflammatory Drugs Market 2025-2033 Analysis: Trends, Competitor Dynamics, and Growth Opportunities

Non-steroidal Anti-Inflammatory Drugs (NSAIDs) Market Is Set To Reach 15.58 USD billion By 2033, Growing At A CAGR Of 21.2

Rheumatoid Arthritis Therapeutics Market XXX CAGR Growth Outlook 2025-2033

Tailored for you

In-depth Analysis Tailored to Specified Regions or Segments
Company Profiles Customized to User Preferences
Comprehensive Insights Focused on Specific Segments or Regions
Customized Evaluation of Competitive Landscape to Meet Your Needs
Tailored Customization to Address Other Specific Requirements

Ask for customization

The response was good, and I got what I was looking for as far as the report. Thank you for that.

Erik Perison

US TPS Business Development Manager at Thermon

As requested- presale engagement was good, your perseverance, support and prompt responses were noted. Your follow up with vm’s were much appreciated. Happy with the final report and post sales by your team.

Shankar Godavarti

Global Product, Quality & Strategy Executive- Principal Innovator at Donaldson

I have received the report already. Thanks you for your help.it has been a pleasure working with you. Thank you againg for a good quality report